1
|
Labadie M, Langrand J, Leroux G, Manel J, Nisse P, Sapori JM, Tournoud C, Sinno-Tellier S, Greillet C, Solal C. Exposures associated with making or playing with viscoelastic polymer toys known as Slime: a retrospective case series from French Poison Control Centres. Clin Toxicol (Phila) 2019; 58:482-487. [PMID: 31475854 DOI: 10.1080/15563650.2019.1657144] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Context: Slime is a slow-flowing material with viscoelastic properties which is attractive to children. Its preparation is based on the crosslinking of polyvinyl alcohol, polyvinyl acetate or starch with boric acid.Objectives: The goal of this study was to describe the adverse effects of Slime.Materials and methods: This is a descriptive retrospective study of cases of exposure reported to French Poison Control Centres between January 2014 and May 2018. The following parameters were used: age and sex, date and circumstances of exposure, symptoms and severity.Results: Two hundred and eight (208) cases of exposure were recorded, 93 cases happened in 2017, and 88 cases in the first four and a half months of 2018. The average age was of 8 years old; 190 patients were younger than 15. Fifty-seven percent (57%) were female. Regarding routes of exposure, 168 were oral, 30 cutaneous, eight ocular, one inhalation and one ear exposure. Eighty-two (82) patients were symptomatic, including 81 cases of low severity and one of average severity (keratitis). All cases lead to recovery.Conclusion: No significant adverse health effects are expected to develop if only small amounts are swallowed; making Slime with home ingredients is a potential cause of boric acid exposure that must be supervised by adults.
Collapse
Affiliation(s)
- M Labadie
- Centre Antipoison, Centre Hospitalier Universitaire, Bordeaux, France
| | - J Langrand
- Centre antipoison de Paris, Fédération de toxicologie, APHP Hôpital Lariboisière Fernand Widal, Paris, France
| | - G Leroux
- Centre Antipoison, Centre Hospitalier Universitaire, Angers, France
| | - J Manel
- Centre Antipoison, Centre Hospitalier Universitaire, Nancy, France
| | - P Nisse
- Centre Antipoison, CHRU, Lille, France
| | - J M Sapori
- Centre Antipoison, Hospices Civils de Lyon, Lyon, France
| | - C Tournoud
- Centre Antipoison, Centre Hospitalier Universitaire, Nancy, France
| | - S Sinno-Tellier
- ANSES, Direction Alertes et Veille sanitaires, Paris, France
| | - C Greillet
- ANSES, Direction Alertes et Veille sanitaires, Paris, France
| | - C Solal
- ANSES, Direction Alertes et Veille sanitaires, Paris, France
| |
Collapse
|
2
|
Droitcourt C, Nowak E, Rault C, Happe A, Le Nautout B, Kerbrat S, Balusson F, Poizeau F, Travers D, Sapori JM, Lagarde E, Rey G, Guillot B, Oger E, Dupuy A. Risk of suicide attempt associated with isotretinoin: a nationwide cohort and nested case-time-control study. Int J Epidemiol 2019; 48:1623-1635. [DOI: 10.1093/ije/dyz093] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/12/2019] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Isotretinoin is the only effective treatment for severe acne. An isotretinoin-related suicide risk is still debated and under scrutiny by regulatory agencies. Our objectives were: to assess the risk of suicide attempt before, during and after isotretinoin treatment; to detect any potential triggering effect of isotretinoin initiation on suicide attempt.
Methods
We implemented a cohort and nested case-time-control study of subjects treated with oral isotretinoin (course or initiation) aged 10–50 years, using the Nationwide French Health Insurance data (2009–2016). The main outcome was hospitalized suicide attempt. Standardized incidence ratios for hospitalized suicide attempts were calculated before, during and after isotretinoin treatment. The number of isotretinoin initiations was compared in risk and control periods of 2 months using a case-time-control analysis.
Results
In all, 443 814 patients (median age 20.0 years; interquartile range 17.0–27.0 years) were exposed to isotretinoin, amounting to 244 154 person-years, with a marked seasonality for treatment initiation. Compared with the French general population, the occurrence of suicide attempts under isotretinoin treatment was markedly lower, with a standardized incidence ratio of 0.6 [95% confidence interval (CI) = 0.53–0.67]; the same applied, to a lesser extent, before and after isotretinoin treatment. In the case-time-control analysis, among cases of suicide attempt, 108 and 127 isotretinoin initiations were observed in the risk and control periods respectively (i.e. 0–2 months and 2–4 months before the date of suicide attempt). The comparison with the 1199 and 1253 initiations observed among matched controls in the same two periods yielded a case-time-control odds ratio of 0.89 (95% CI = 0.68–1.16). A sensitivity analysis using three-month periods and a complementary analysis adding completed suicides for case definition showed consistent results.
Conclusion
Compared with the general population, a lower risk of suicide attempt was observed among patients exposed to isotretinoin and there was no evidence for a triggering effect of isotretinoin initiation on suicide attempt. A selection of patients at lower risk for suicidal behaviour and appropriate treatment management could explain these findings. Risk management plans should therefore be maintained.
Collapse
Affiliation(s)
- Catherine Droitcourt
- Univ Rennes, EA 7449 REPERES [Pharmacoepidemiology and Health Services Research]
- PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France
- Department of Dermatology, CHU Rennes, Rennes, France
- INSERM, CIC 1414, Rennes, France
| | - Emmanuel Nowak
- PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France
- University of Bretagne Loire, University of Brest, France
- INSERM CIC 1412, CHRU Brest, Brest, France
| | - Caroline Rault
- Univ Rennes, EA 7449 REPERES [Pharmacoepidemiology and Health Services Research]
- PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France
| | - André Happe
- Univ Rennes, EA 7449 REPERES [Pharmacoepidemiology and Health Services Research]
- PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France
| | - Béranger Le Nautout
- Univ Rennes, EA 7449 REPERES [Pharmacoepidemiology and Health Services Research]
- PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France
| | - Sandrine Kerbrat
- Univ Rennes, EA 7449 REPERES [Pharmacoepidemiology and Health Services Research]
- PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France
| | - Frédéric Balusson
- Univ Rennes, EA 7449 REPERES [Pharmacoepidemiology and Health Services Research]
- PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France
| | - Florence Poizeau
- Univ Rennes, EA 7449 REPERES [Pharmacoepidemiology and Health Services Research]
- PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France
- Department of Dermatology, CHU Rennes, Rennes, France
| | - David Travers
- Department of Psychiatry, CHU Rennes, Rennes, France
| | | | - Emmanuel Lagarde
- INSERM, ISPED, Bordeaux Population Health Research Center INSERM U219 – “Injury Epidemiology Transport Occupation” Team, Bordeaux Cedex, France
| | | | - Bernard Guillot
- Department of Dermatology, CHU Montpellier, Montpellier, France
| | - Emmanuel Oger
- Univ Rennes, EA 7449 REPERES [Pharmacoepidemiology and Health Services Research]
- PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France
| | - Alain Dupuy
- Univ Rennes, EA 7449 REPERES [Pharmacoepidemiology and Health Services Research]
- PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France
- Department of Dermatology, CHU Rennes, Rennes, France
| |
Collapse
|
3
|
Redaelli M, Brunet D, Langlois E, Robert S, Certin JF, Bertrand N, Sapori JM, Roudot AC, Verines-Jouin L. Professionnels du soin et de la décoration de l’ongle : une population exposée à de nombreuses substances chimiques. ARCH MAL PROF ENVIRO 2018. [DOI: 10.1016/j.admp.2018.03.389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
4
|
Pelissier F, de Haro L, Cardona F, Picot C, Puskarczyk E, Sapori JM, Tournoud C, Franchitto N. Self-poisoning with baclofen in alcohol-dependent patients: national reports to French Poison Control Centers, 2008–2013. Clin Toxicol (Phila) 2017; 55:275-284. [DOI: 10.1080/15563650.2017.1284330] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Fanny Pelissier
- Poison Control Center, Toulouse-Purpan University Hospital, Toulouse, France
| | - Luc de Haro
- Poison Control Center, Clinical Pharmacology Department, Sainte Marguerite Hospital, Marseille, France
- Groupe de Travail Toxicovigilance des Médicaments, ANSM, Saint Denis, France
- Comité de Coordination de Toxicovigilance, Institut de Veille Sanitaire (InVS), Saint Maurice, France
| | - Florence Cardona
- Groupe de Travail Toxicovigilance des Médicaments, ANSM, Saint Denis, France
- French National Agency for Medicines and Health Products Safety (ANSM), Saint Denis, France
| | - Cyndie Picot
- Groupe de Travail Toxicovigilance des Médicaments, ANSM, Saint Denis, France
- Comité de Coordination de Toxicovigilance, Institut de Veille Sanitaire (InVS), Saint Maurice, France
- French National Agency for Medicines and Health Products Safety (ANSM), Saint Denis, France
| | - Emmanuel Puskarczyk
- Comité de Coordination de Toxicovigilance, Institut de Veille Sanitaire (InVS), Saint Maurice, France
- Poison Information and Toxicovigilance Center, Nancy University Medical Center, Nancy, France
| | - Jean-Marc Sapori
- Comité de Coordination de Toxicovigilance, Institut de Veille Sanitaire (InVS), Saint Maurice, France
- Toxicovigilance and Poison Control Center, Hospices Civils de Lyon, Lyon, France
| | - Christine Tournoud
- Groupe de Travail Toxicovigilance des Médicaments, ANSM, Saint Denis, France
- Comité de Coordination de Toxicovigilance, Institut de Veille Sanitaire (InVS), Saint Maurice, France
- Poison Information and Toxicovigilance Center, Hôpital Civil, Strasbourg, France
| | - Nicolas Franchitto
- Poison Control Center, Toulouse-Purpan University Hospital, Toulouse, France
- Groupe de Travail Toxicovigilance des Médicaments, ANSM, Saint Denis, France
- Comité de Coordination de Toxicovigilance, Institut de Veille Sanitaire (InVS), Saint Maurice, France
- Department of Addiction Medicine, Toulouse-Purpan University Hospital, Toulouse, France
| |
Collapse
|
5
|
Lajoinie A, Henin E, Nguyen KA, Malik S, Mimouni Y, Sapori JM, Bréant V, Cochat P, Kassai B. Oral drug dosage forms administered to hospitalized children: Analysis of 117,665 oral administrations in a French paediatric hospital over a 1-year period. Int J Pharm 2016; 500:336-44. [PMID: 26804927 DOI: 10.1016/j.ijpharm.2016.01.048] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2015] [Revised: 01/18/2016] [Accepted: 01/19/2016] [Indexed: 11/16/2022]
Abstract
Selecting the most appropriate dosage form, that ensures safe administration and adherence of medications, is a major issue for children. Marketed drugs, however, have rarely been tested for their use in children. There is a need for more data on drug formulations administered to children to identify unmet needs, and drive future paediatric research. We observed, over a 12-month follow-up, 117,665 oral drug administrations to 1998 hospitalized children. Nine-tenths belonged to five Anatomical Therapeutic Chemical classes: Alimentary tract & metabolism, Nervous system, Cardiovascular system, Anti-infectives for systemic use and Blood & blood forming organs, one third of drug doses administered to school-age children and adolescents were liquids, and extemporaneous capsules were commonly used in younger children. Our study shows that despite the advantages of solid dosage forms and recent evidence from randomized controlled trials showing their acceptability in infants, they are seldom used in paediatric practice.
Collapse
Affiliation(s)
- A Lajoinie
- Clinical Investigation Centre CIC-INSERM 1407, EPICIME, Department of Clinical Pharmacology, Hospices Civils de Lyon, France; UMR CNRS 5558, Laboratoire de Biométrie et Biologie Evolutive, University of Lyon 1, France.
| | - E Henin
- UMR CNRS 5558, Laboratoire de Biométrie et Biologie Evolutive, University of Lyon 1, France
| | - K A Nguyen
- Clinical Investigation Centre CIC-INSERM 1407, EPICIME, Department of Clinical Pharmacology, Hospices Civils de Lyon, France
| | - S Malik
- Clinical Investigation Centre CIC-INSERM 1407, EPICIME, Department of Clinical Pharmacology, Hospices Civils de Lyon, France
| | - Y Mimouni
- Clinical Investigation Centre CIC-INSERM 1407, EPICIME, Department of Clinical Pharmacology, Hospices Civils de Lyon, France
| | - J M Sapori
- Toxicovigilance and Poison Control Center, Hospices Civils de Lyon, France
| | - V Bréant
- Department of Pharmacy, Hospices Civils de Lyon, France
| | - P Cochat
- Clinical Investigation Centre CIC-INSERM 1407, EPICIME, Department of Clinical Pharmacology, Hospices Civils de Lyon, France; Department of Pediatric Nephrology, Hopital Femme Mere Enfant, Hospices Civils de Lyon, France
| | - B Kassai
- Clinical Investigation Centre CIC-INSERM 1407, EPICIME, Department of Clinical Pharmacology, Hospices Civils de Lyon, France; UMR CNRS 5558, Laboratoire de Biométrie et Biologie Evolutive, University of Lyon 1, France
| |
Collapse
|
6
|
Jollivet V, Hamel JF, de Haro L, Labadie M, Sapori JM, Cordier L, Villa A, Nisse P, Puskarczyk E, Berthelon L, Harry P, Boels D. European viper envenomation recorded by French poison control centers: A clinical assessment and management study. Toxicon 2015; 108:97-103. [PMID: 26454165 DOI: 10.1016/j.toxicon.2015.09.039] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2015] [Revised: 08/20/2015] [Accepted: 09/29/2015] [Indexed: 11/25/2022]
Abstract
INTRODUCTION Immunotherapy is the gold standard treatment for patients bitten by European vipers in France; it significantly decreases morbidity, frequency and severity of complications and length of stay. A national prospective study was performed by all Poison Control Centers (PCC) to validate the emergency protocol for viper envenomations. METHODS This prospective study included all cases of viper bites in France, treated or not with Viperfav(®) in 2013. RESULTS In 2013, 277 cases of viper bites were collected: ratio M/F 2.1; mean aged 43 years (<15 years 25% 15-65 63% > 65 12%). The final severity was divided into 68 grades 0, 58 grades I, 62 grades IIA, 71 grades IIB and 18 grades III. One death was reported. Five patients had neurological signs. For the 114 patients who received Viperfav(®), all systemic signs disappeared in 5 h and in 24 h for biological and neurological signs. No severe anaphylactic reaction with Viperfav(®) was reported. Late Viperfav(®) administration increased the risk of functional impairment 15 days after the bite (OR = 3.21 p = 0.043). The administration of Low Molecular Weight Heparin (LMWH) increased the frequency of functional impairment to 15 days after the bite (OR = 6.38 p = 0.064), although Viperfav(®) was given in the first 18 h. DISCUSSION This study confirms the efficiency, safety and recommendation of an early administration of a single dose of Viperfav(®), LMWH should not be used. It also shows the extension of neurotoxic venom of vipers in France.
Collapse
Affiliation(s)
- V Jollivet
- Poison Control Center, Angers University Hospital, France
| | - J F Hamel
- Clinical Research Center, Angers University Hospital, France
| | - L de Haro
- Poison Control Center, Marseille University Hospital, France
| | - M Labadie
- Poison Control Center, Bordeaux University Hospital, France
| | - J M Sapori
- Poison Control Center, Lyon University Hospital, France
| | - L Cordier
- Poison Control Center, Toulouse University Hospital, France
| | - A Villa
- Poison Control Center, Paris University Hospital, France
| | - P Nisse
- Poison Control Center, Lille University Hospital, France
| | - E Puskarczyk
- Poison Control Center, Nancy University Hospital, France
| | - L Berthelon
- Poison Control Center, Strasbourg University Hospital, France
| | - P Harry
- Poison Control Center, Angers University Hospital, France
| | - D Boels
- Poison Control Center, Angers University Hospital, France.
| |
Collapse
|
7
|
Sapori JM. Multiplication des alertes sanitaires dans les médias : quelle pertinence ? Presse Med 2013; 42:1298-9. [DOI: 10.1016/j.lpm.2013.07.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
8
|
Glaizal M, Schmitt C, Tichadou L, Sapori JM, Hayek-Lanthois M, de Haro L. Intoxications induites par de la farine de sarrasin Bio contaminée par Datura Sp. : rôle d’un centre antipoison et de toxicovigilance. Presse Med 2013; 42:1412-5. [DOI: 10.1016/j.lpm.2013.04.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2012] [Revised: 03/29/2013] [Accepted: 04/12/2013] [Indexed: 10/26/2022] Open
|
9
|
Blakey DH, Lafontaine M, Lavigne J, Sokolowski D, Philippe JM, Sapori JM, Biederbick W, Horre R, Marzi WB, Kondo H, Kuroki Y, Namera A, Okumura T, Yamamoto M, Yashiki M, Blain PG, Russell DR, Cibulsky SM, Jett DA. A screening tool to prioritize public health risk associated with accidental or deliberate release of chemicals into the atmosphere. BMC Public Health 2013; 13:253. [PMID: 23517410 PMCID: PMC3751112 DOI: 10.1186/1471-2458-13-253] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2012] [Accepted: 02/19/2013] [Indexed: 11/10/2022] Open
Abstract
The Chemical Events Working Group of the Global Health Security Initiative has developed a flexible screening tool for chemicals that present a risk when accidentally or deliberately released into the atmosphere. The tool is generic, semi-quantitative, independent of site, situation and scenario, encompasses all chemical hazards (toxicity, flammability and reactivity), and can be easily and quickly implemented by non-subject matter experts using freely available, authoritative information. Public health practitioners and planners can use the screening tool to assist them in directing their activities in each of the five stages of the disaster management cycle.
Collapse
Affiliation(s)
- David H Blakey
- Chemical Events Working Group of the Global Health Security Initiative, Berlin, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Sapori JM, Meyran S, Berthaud S, Descotes J, Rouzioux JM. [Cyanide poisoning. Evaluation of 15 years of phone calls to the Anti-Poison Center and autopsies at the Institute of Forensic Medicine]. J Toxicol Clin Exp 1992; 12:353-9. [PMID: 1295993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- J M Sapori
- Centre Anti-Poisons, Hôpital H. Herriot, Lyon, France
| | | | | | | | | |
Collapse
|
11
|
Scalbert J, Coppere B, Meyran S, Sapori JM, Ducluzeau R, Minet J, Rouzioux JM. [Epidemiology of emergency department hospitalizations for poisoning by industrial products]. J Toxicol Clin Exp 1992; 12:197-203. [PMID: 1295969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- J Scalbert
- Service de Médecine d'Urgence, Hopital Edouard Herriot, Lyon, France
| | | | | | | | | | | | | |
Collapse
|
12
|
Piperno D, Sapori JM, Caillet B, Ducluzau R, Perrin-Fayolle M. [Pneumomediastinum after 24 hours of swimming]. Presse Med 1990; 19:1723. [PMID: 2147492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
|